DorsaVi is packing up and moving to the land of opportunity, the US of A.

The company (ASX:DVL) told investors today that chief Andrew Ronchi has already made the move, joining the US subsidiary and taking with him a package of $US300,000 ($374,000).

The company got approval from the powerful US Food and Drug Administration for a sensor that can measure the way muscles in the lower back move — but has been selling into the US market since 2014.

DorsaVi says Mr Ronchi’s move is part of a new focus on the US, where they want to grow annuity revenue, or guaranteed income, in the clinical and occupational health and safety markets.

“Compared to Australia, the US clinical market is more advanced in its acceptance of data-driven decision making, evident in the quicker scale up of the company’s clinical business in the US,” it told investors.

Taking Mr Ronchi’s place in Australia will be the head of sales and operations, Matt May, who will become general manager.

The company has been contacted for comment.

DorsasVi's share price since it listed in December 2013.
DorsasVi’s share price since it listed in December 2013.